PTPRC and cancer: Flow cytometry revealed a significant reduction in the percentage of CD45+ cancer cells in the peripheral blood of the mice received PKMYT1‐knockdown K562 cells, compared with that in the peripheral blood of the mice of wild‐type group (Figure 7g).